April 16, 2026
If you prescribe compounded peptides, or work with patients who use them, a notice published this week in the Federal Register deserves your close attention. The FDA has announced a two-day public meeting of its Pharmacy Compounding Advisory Committee (PCAC) on July 23–24, 2026, to formally evaluate whether seven bulk drug substances should be added to the Section 503A Bulk Drug Substances List (the “503A Bulks List”). The outcome of this process will have real, practical consequences for how providers can legally prescribe these compounds.
The Substances on the Table
These are the drugs being reviewed and the medical uses FDA will be evaluating:
July 23, 2026:
- BPC-157 (free base and acetate) — ulcerative colitis
- KPV (free base and acetate) — wound healing and inflammatory conditions
- TB-500 (free base and acetate) — wound healing
- MOTs-C (free base and acetate) — obesity and osteoporosis
July 24, 2026:
- Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) — opioid withdrawal, chronic insomnia, and narcolepsy
- Semax (free base and acetate) — cerebral ischemia, migraine, and trigeminal neuralgia
- Epitalon (free base and acetate) — insomnia
If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients.
Why This Matters: A Quick Primer on Section 503A
Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), human drug products compounded by a licensed pharmacist in a state-licensed pharmacy — or by a licensed physician — can be exempt from three major FDA requirements: current Good Manufacturing Practice (cGMP) standards, certain labeling requirements, and the standard new drug approval process (NDAs/ANDAs). These are significant exemptions, and they are what make patient-specific compounding legally viable.
The catch is that a compounded drug product qualifies for these exemptions only if the bulk drug substance used to make it meets one of three criteria: (1) it complies with a USP or National Formulary monograph; (2) it is a component of an FDA-approved drug; or (3) it appears on the 503A Bulks List, which is a list the FDA develops through regulation. Most of the peptides being reviewed — BPC-157, TB-500, MOTs-C, Semax, Epitalon, and the others — do not currently have USP monographs and are not components of FDA-approved drugs. That puts them squarely in the third category, meaning their legal use in compounding hinges almost entirely on whether they make it onto the 503A Bulks List.
For years, many of these peptides have existed in a regulatory gray zone, widely prescribed by integrative and functional medicine providers while their official status remained unresolved. This advisory committee meeting is a formal step in the process of resolving that uncertainty — one way or the other.
What This Process Looks Like Step by Step
Understanding the procedural timeline is essential for providers and their counsel who want to participate or simply stay informed.
Now through July 9, 2026 — Comment Window for the Committee. The public docket (FDA-2025-N-6895) is open for written comments at regulations.gov. Any comments submitted by July 9 will be formally provided to the PCAC members ahead of the meeting. This is the most impactful window for providers, medical societies, patient advocates, and compounding pharmacies to submit clinical data, practice experience, or policy arguments. Comments submitted after July 9 but before the July 22 docket closure will still be considered by FDA, but will not go directly to the Committee.
June 30, 2026 — Deadline to Register for Oral Testimony. Individuals or organizations who wish to give a formal oral presentation at the meeting must notify FDA by this date. Notifications must include a brief description of the evidence or arguments to be presented, the names and addresses of participants, a preference for in-person or virtual attendance, and a requested time allotment. If more people register than can be accommodated, FDA may hold a lottery to select speakers. Presenters will be notified by July 1, 2026.
July 22, 2026 — Docket Closes. This is the hard deadline for all public written comment submissions via regulations.gov (by 11:59 p.m. Eastern Time) or by mail/courier.
July 23–24, 2026 — PCAC Meeting. The two-day meeting will be held at FDA’s White Oak Campus in Silver Spring, Maryland, with a virtual attendance option. On Day 1, the Committee will discuss BPC-157, KPV, TB-500, and MOTs-C. On Day 2, the focus shifts to Emideltide (DSIP), Semax, and Epitalon. Nominators of each substance will have an opportunity to make a brief supporting presentation. Open public hearing sessions are scheduled throughout both days. FDA intends to publish background materials at least two business days before the meeting.
After the Meeting — Rulemaking. The PCAC’s role is advisory: it provides recommendations to FDA, but does not make binding decisions. FDA will consider the Committee’s guidance and, if it concludes a substance is appropriate, will initiate the rulemaking process required to formally add it to the 503A Bulks List. That process involves its own notice-and-comment period and can take additional months. Listing on the 503A Bulks List is ultimately the point at which providers and compounding pharmacies have clear legal footing.
What Prescribers Should Be Doing Right Now
Evaluate your current prescribing practices. If you are currently prescribing any of these peptides through a compounding pharmacy, now is the time to confirm that your pharmacy is 503A-compliant and to understand what the absence of a formal Bulks List designation means for the current legality of those prescriptions. The regulatory risk is real and worth a candid conversation with legal counsel.
Consider submitting written comments. The public comment process is not just a formality. FDA and the PCAC do review clinical input from practitioners, and well-documented comments describing clinical outcomes, patient need, or safety observations can meaningfully inform the Committee’s recommendations. If you or your practice has experience with any of these substances, the docket is an appropriate forum to share that information.
Watch for the background materials. FDA will post its own background review of each substance at least two business days before the meeting. These materials will contain FDA’s preliminary analysis of the clinical evidence, safety data, and any concerns. Reviewing them before or during the meeting will give providers important insight into how FDA is currently weighing these substances.
Do not assume listing is a foregone conclusion. The fact that these substances have been nominated and are being reviewed does not mean they will be added to the 503A Bulks List. The Committee may recommend inclusion, rejection, or request additional data. Some substances may face more scrutiny than others based on available safety data or the adequacy of evidence supporting the nominated uses. Providers should not make long-term practice decisions predicated on an outcome that has not yet occurred.
The Bigger Picture
This advisory committee meeting is part of a broader and ongoing effort by FDA to impose order on the compounding landscape, particularly with respect to peptides and biologics that have grown popular in wellness, sports medicine, longevity, and integrative health settings. FDA’s scrutiny of these substances reflects a legitimate concern about ensuring that compounded products are safe and that clinical claims are substantiated — but it also creates very real uncertainty for providers and patients who have relied on these compounds.
The stakes are high on both sides: for patients who depend on these treatments, and for providers who face potential enforcement risk if they continue prescribing compounds that ultimately are not approved for the 503A Bulks List. The July meeting is a pivotal moment in that process, and the window to participate meaningfully is open right now.